FDA Orange Book: How to Search Approved Drug Products and Patents
The FDA Orange Book, officially titled "Approved Drug Products with Therapeutic Equivalence Evaluations," is FDA's comprehensive database of all approved prescription and over-the-counter drug products. It lists therapeutic equivalence (TE) ratings (e.g., AB, AP, AT), patent information, and exclusivity periods for each approved drug. The Orange Book is essential for generic drug development because it identifies reference listed drugs (RLDs), specifies which patents must be addressed in ANDA submissions, and indicates when generic competition can begin. It is available as a searchable online database at FDA.gov and as an annual print edition with monthly supplements.
Key Takeaways
Key Takeaways
- The Orange Book lists all drug products approved under Section 505 of the FD&C Act, including therapeutic equivalence (TE) codes, patent information, and exclusivity periods
- AB-rated products are therapeutically equivalent and eligible for automatic pharmacy substitution in most states; B-rated products are not considered equivalent
- NDA holders must list drug substance, drug product, and method-of-use patents (but not process patents) on Form FDA 3542 within 30 days of approval or patent issuance
- Five-year NCE exclusivity prevents ANDA submission until Year 4 (with Paragraph IV) or Year 5, while 3-year NCI exclusivity blocks ANDA approval but not submission
- The FDA Orange Book is one of the most consequential regulatory publications in pharmaceutical development. Formally titled "Approved Drug Products with Therapeutic Equivalence Evaluations," this database serves as the definitive reference for drug product approval status, therapeutic equivalence determinations, patent listings, and exclusivity information.
- For generic drug developers, the Orange Book is the starting point for every ANDA. It identifies reference listed drugs, catalogs the patents that must be addressed through paragraph certifications, and specifies exclusivity periods that may block generic approval. For pharmacists, it determines which generic products may be automatically substituted for brand drugs.
- In this guide, you'll learn:
- What the Orange Book is and its legal authority
- How to search the Orange Book database effectively
- Therapeutic equivalence (TE) evaluation codes explained
- How patent listings work and what they mean for generics
- Exclusivity periods and their impact on generic competition
- How the Orange Book differs from the Purple Book
- Practical use of Orange Book data in ANDA development
- ---
What Is the FDA Orange Book?
The FDA Orange Book is a publication maintained by FDA's Center for Drug Evaluation and Research (CDER) that lists all drug products approved under Section 505 of the Federal Food, Drug, and Cosmetic Act. It includes therapeutic equivalence evaluations for approved multi-source drugs, patent information submitted by NDA holders, and exclusivity data. Its formal title is "Approved Drug Products with Therapeutic Equivalence Evaluations."
Legal Authority
The Orange Book's authority derives from several statutory and regulatory provisions:
| Authority | Provision |
|---|---|
| Drug listing requirement | Section 505 of the FD&C Act |
| Patent listing obligation | Section 505(b)(1) and 505(c)(2) of the FD&C Act |
| Therapeutic equivalence evaluation | 21 CFR 314.3 and FDA policy |
| Publication mandate | Section 505(j)(7)(A) of the FD&C Act |
| Exclusivity information | Sections 505(c)(3)(E), 505(j)(5)(F), 505(j)(5)(D) |
Publication Format
The Orange Book is published in multiple formats:
| Format | Description | Update Frequency |
|---|---|---|
| Online database | Searchable at FDA.gov (Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations) | Daily |
| Annual print edition | Comprehensive volume with all listings | Annually (typically January) |
| Monthly supplements | Cumulative supplements to annual edition | Monthly |
| Data files | Downloadable data files in text/zip format | Monthly |
The online database (accessible at fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book) is the most current and is the recommended reference for regulatory work.
What the Orange Book Contains
| Data Element | Description |
|---|---|
| Approved drug products | All NDA and ANDA-approved products with active ingredient, dosage form, strength, route |
| Therapeutic equivalence codes | TE ratings for all multi-source products |
| Patent information | Drug substance patents, drug product patents, method-of-use patents |
| Exclusivity data | NCE exclusivity, clinical investigation exclusivity, orphan exclusivity, pediatric exclusivity |
| Reference listed drug (RLD) designation | Which approved product is designated as the RLD for ANDA referencing |
| Applicant information | NDA/ANDA holder name |
The Orange Book lists over 35,000 approved drug products, including approximately 12,000 prescription drug products and their approved generic equivalents.
How to Search the FDA Orange Book
Searching the Orange Book effectively is a critical skill for regulatory professionals. The online database offers several search methods.
Search by Active Ingredient
The most common search approach for generic drug development:
- Navigate to FDA's Orange Book search page
- Enter the active ingredient name (use the established/generic name, not the brand name)
- Review all approved products containing that ingredient
- Identify the RLD (marked with "RLD" designation)
- Note the TE ratings for approved generics
- Check patent and exclusivity listings
Search by Proprietary (Brand) Name
Useful when starting from a known brand product:
- Enter the brand name in the proprietary name field
- The results show all approved forms and strengths under that brand
- Cross-reference to find approved generics for the same product
Search by Patent Number
When conducting patent landscape analysis:
- Enter the patent number in the patent search field
- Results show all drug products listing that patent
- Useful for identifying all products potentially affected by a single patent
Search by Application Number
When working with a specific NDA or ANDA:
- Enter the NDA or ANDA number
- Results show the specific approved product and all associated data
- Useful for tracking individual application status
Interpreting Search Results
Each Orange Book listing displays:
| Field | Meaning |
|---|---|
| Ingredient | Active pharmaceutical ingredient (established name) |
| DF;Route | Dosage form and route of administration |
| Strength | Amount of active ingredient per unit |
| Proprietary Name | Brand/trade name |
| Applicant | Company holding the approval |
| Appl. No. | NDA or ANDA number |
| Product No. | Specific product within an application |
| TE Code | Therapeutic equivalence rating |
| Approval Date | Date of FDA approval |
| RLD | "Yes" if designated as reference listed drug |
| RS | "Yes" if designated as reference standard |
| Type | RX (prescription) or OTC (over-the-counter) |
When researching a product for ANDA development, always search by active ingredient rather than brand name. This reveals all approved forms, strengths, and manufacturers, including the RLD designation, which is essential for identifying the correct reference product.
Therapeutic Equivalence Evaluation Codes Explained
Therapeutic equivalence (TE) ratings are the Orange Book's most operationally significant data element. These codes determine whether a generic drug can be automatically substituted for the brand product at the pharmacy level.
The TE Rating System
TE codes follow a two-letter system where the first letter indicates the primary equivalence determination:
| First Letter | Meaning |
|---|---|
| A | Drug products FDA considers therapeutically equivalent to the reference product |
| B | Drug products FDA does not consider therapeutically equivalent to the reference product |
A-Rated Products (Therapeutically Equivalent)
A-rated products are considered therapeutically equivalent and are eligible for generic substitution in most states.
| TE Code | Meaning | Basis for Rating |
|---|---|---|
| AB | Meets bioequivalence requirements | In vivo and/or in vitro bioequivalence demonstrated |
| AN | Aerosol products meeting BE requirements | Solution-based aerosols with equivalent formulations |
| AO | Injectable oil solutions | Equivalent active ingredient in same oil vehicle |
| AP | Injectable aqueous solutions | Equivalent strength and formulation |
| AT | Topical products | Equivalent formulation with demonstrated BE |
AB-rated products are the most common TE designation for orally administered generics. An AB rating means the generic has demonstrated bioequivalence to the RLD through adequate in vivo or in vitro studies and may be substituted at the pharmacy.
AB rating subcategories: When multiple generics are approved and some are not bioequivalent to each other (only to the RLD), FDA assigns numerical subscripts (AB1, AB2, AB3) to distinguish substitution groups. Products sharing the same AB subscript number are considered therapeutically equivalent to each other. Products with different subscript numbers should not be substituted for each other.
B-Rated Products (Not Therapeutically Equivalent)
B-rated products are not considered therapeutically equivalent and generally cannot be substituted without prescriber approval.
| TE Code | Meaning |
|---|---|
| BC | Extended-release dosage forms with different release mechanisms |
| BD | Active ingredient and dosage form same but insufficient BE data |
| BE | Delayed-release enteric-coated products with unresolved BE questions |
| BN | Aerosol products that are not equivalent |
| BP | Active ingredient same but not standard pharmaceutical equivalents |
| BR | Suppository or enema forms with unresolved BE questions |
| BS | Drug products with known bioequivalence problems |
| BT | Topical products with unresolved BE questions |
| BX | Insufficient data to determine therapeutic equivalence |
How TE Ratings Affect Generic Substitution
| TE Rating | Substitution Permitted | Prescriber Authorization Required |
|---|---|---|
| A-rated (any) | Yes, in most states | No (automatic substitution allowed) |
| B-rated (any) | No (in most states) | Yes (prescriber must specifically authorize) |
State pharmacy practice acts govern generic substitution rules. Most states require pharmacists to substitute A-rated generics unless the prescriber indicates "dispense as written" or "no substitution."
Approximately 90% of generic prescriptions dispensed in the United States involve A-rated (primarily AB-rated) products, according to the Association for Accessible Medicines.
Patent Listings in the Orange Book
NDA holders are required to submit patent information to FDA for listing in the Orange Book. These listings directly impact generic drug development by defining the patents that ANDA applicants must address through paragraph certifications.
What Patents Can Be Listed
Under Section 505(b)(1) and 505(c)(2) of the FD&C Act, NDA holders must submit information for patents that:
| Patent Type | Description | Listable |
|---|---|---|
| Drug substance (API) patent | Claims the active pharmaceutical ingredient itself | Yes |
| Drug product patent | Claims the finished dosage form, formulation, or composition | Yes |
| Method of use patent | Claims an approved indication or method of treatment | Yes |
| Process patent | Claims the manufacturing process only | No |
| Metabolite patent | Claims an active metabolite | No (unless metabolite is the active ingredient) |
| Packaging patent | Claims the packaging or container | No |
| Intermediate patent | Claims a synthetic intermediate | No |
Patent Listing Requirements
NDA holders must submit patent information on Form FDA 3542 (for new patents) or Form FDA 3542a (for amended patent listings) within 30 days of NDA approval or patent issuance, whichever is later.
Required information per listing:
- Patent number
- Patent expiration date
- Drug substance, drug product, or method of use designation
- Claims of the patent that cover the approved drug product
- Any patent term extension or pediatric exclusivity additions
How Patent Listings Affect ANDA Development
Each patent listed in the Orange Book for the RLD must be addressed in the ANDA through a paragraph certification (I, II, III, or IV) under 21 CFR 314.94(a)(12). This creates a direct link between Orange Book patent data and the generic drug approval timeline:
| Number of Listed Patents | Certification Burden | Strategic Complexity |
|---|---|---|
| 0 patents | Paragraph I certification | Minimal |
| 1-3 patents | Certifications per patent; mixed strategies possible | Moderate |
| 4-10 patents | Multiple certifications; higher litigation risk | High |
| 10+ patents | Extensive patent landscape analysis required | Very high |
Patent Listing Challenges
ANDA applicants can challenge improper Orange Book patent listings through several mechanisms:
- Counterclaim in Paragraph IV litigation: Challenge the propriety of the listing as part of infringement defense
- Citizen petition to FDA: Request delisting of improperly listed patents under 21 CFR 314.53
- FTC complaint: Report anti-competitive patent listing practices
Always verify Orange Book patent data against the U.S. Patent and Trademark Office (USPTO) database. Patent expiration dates in the Orange Book include any patent term extensions (PTEs) and pediatric exclusivity additions. Cross-referencing USPTO and Orange Book data ensures accurate patent landscape assessment for ANDA planning.
Exclusivity Periods Listed in the Orange Book
In addition to patents, the Orange Book lists various exclusivity periods that may prevent or delay generic approval. Unlike patents (which are property rights), exclusivities are statutory provisions that prevent FDA from approving or, in some cases, accepting ANDAs for specified periods.
Types of Exclusivity
| Exclusivity Type | Duration | Statutory Basis | Effect on ANDAs |
|---|---|---|---|
| New Chemical Entity (NCE) | 5 years | 505(c)(3)(E)(ii) | No ANDA may be submitted for 5 years (4 years with Paragraph IV) |
| New Clinical Investigation (NCI) | 3 years | 505(c)(3)(E)(iii)-(iv) | ANDA may be submitted but not approved for 3 years |
| Orphan Drug Exclusivity (ODE) | 7 years | Orphan Drug Act, 21 CFR 316 | No ANDA or 505(b)(2) for same drug, same indication for 7 years |
| Pediatric Exclusivity (PED) | 6 months | 505A of FD&C Act | Extends patent and exclusivity periods by 6 months |
| New Patient Population (NP) | 3 years | 505(j)(5)(F)(iv) | Blocks approval for new patient population indication |
| 180-Day Generic Exclusivity | 180 days | 505(j)(5)(B)(iv) | Blocks subsequent ANDA approvals for 180 days |
NCE Exclusivity (5 Years)
Five-year NCE exclusivity is the most significant exclusivity for blocking generic competition:
- Applies to drugs containing active moieties never previously approved by FDA
- No ANDA may be submitted during the first 4 years of NCE exclusivity
- An ANDA with a Paragraph IV certification may be submitted beginning in Year 4
- ANDAs with Paragraph I, II, or III certifications may not be submitted until Year 5
- The 5-year period runs from the date of NDA approval
3-Year NCI Exclusivity
Three-year exclusivity is narrower than NCE exclusivity:
- Applies to NDAs or supplements supported by new clinical investigations (other than bioavailability studies) essential to approval
- Does not block ANDA submission, only ANDA effective approval
- Applies only to the specific condition of approval for which new clinical data was submitted (e.g., new indication, new dosage form)
- Commonly seen with 505(b)(2) NDAs
Orange Book vs. Purple Book
The Orange Book covers drugs approved under Section 505 of the FD&C Act (NDAs and ANDAs). A separate publication, the Purple Book, covers biological products approved under Section 351 of the Public Health Service Act.
Key Differences
| Feature | Orange Book | Purple Book |
|---|---|---|
| Products covered | Small molecule drugs (NDAs, ANDAs) | Biological products (BLAs, biosimilars) |
| Approval pathway | Section 505 of FD&C Act | Section 351 of PHS Act |
| Generic/follow-on pathway | ANDA (505(j)) | Biosimilar (351(k)) |
| Equivalence terminology | Therapeutic equivalence (TE codes) | Biosimilarity and interchangeability |
| Patent listings | Yes (mandatory for NDA holders) | Yes (but under BPCIA "patent dance" framework) |
| Exclusivity types | NCE, NCI, ODE, PED | Reference product exclusivity (12 years), first interchangeable exclusivity |
| Substitution | A-rated = automatic substitution | Interchangeable = automatic substitution |
When to Use Each
- Orange Book: Small molecule drug development, ANDA planning, patent landscape analysis for generics
- Purple Book: Biological product development, biosimilar planning, reference product identification
Using Orange Book Data in ANDA Development
The Orange Book is the foundational reference for ANDA planning. Here is a systematic approach to using Orange Book data:
Step 1: Identify the RLD
Search the Orange Book by active ingredient. The product designated "RLD = Yes" is the reference listed drug that the ANDA must reference. Key considerations:
- Only one product per dosage form/strength combination is typically designated as the RLD
- If the original brand has been discontinued, another approved product may be designated as the RLD or reference standard (RS)
- Use the RS designation to determine which physical product to purchase for BE studies
Step 2: Analyze Patent Landscape
For the identified RLD, review all listed patents:
- Record each patent number, type (substance, product, method of use), and expiration date
- Verify expiration dates include any PTE or pediatric exclusivity extensions
- Cross-reference with USPTO to confirm patent status (active, expired, or lapsed)
- Assess each patent for potential Paragraph IV challenge viability
Step 3: Evaluate Exclusivity Status
Check whether the RLD has any active exclusivity periods:
- NCE exclusivity: Can an ANDA be submitted yet?
- 3-year NCI exclusivity: Can an ANDA be approved yet?
- 180-day generic exclusivity: Is a first-filer's exclusivity blocking approval?
- Orphan drug exclusivity: Is the same drug/indication combination blocked?
Step 4: Assess Competitive Landscape
The Orange Book reveals the full competitive landscape for a generic product:
| Data Point | Strategic Insight |
|---|---|
| Number of approved ANDAs | Market saturation level |
| TE codes of competitors | Whether all generics are AB-rated |
| Tentative approvals | Pipeline of generics awaiting approval |
| Paragraph IV first-filer status | Whether 180-day exclusivity is claimed or forfeited |
References
The online Orange Book database is updated daily with new approvals, patent listings, and exclusivity additions. The print edition is published annually, with cumulative monthly supplements. For regulatory decision-making, always use the online database rather than the print edition, as it reflects the most current data.